Is Arvinas, Inc. overvalued or undervalued?

As of 1 May 2025, the valuation grade for Arvinas, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Notable ratios include a Price to Book Value of 0.83, an EV to EBIT of 11.39, and an ROCE of 12.11%.
In comparison, Arvinas' peers such as Twist Bioscience Corp. and Iovance Biotherapeutics, Inc. have less favorable valuations, with EV to EBITDA ratios of -13.93 and -0.91, respectively. This suggests that Arvinas is positioned more favorably within its industry despite its current loss-making status. Additionally, while the stock has faced significant declines over the past year, it has outperformed the S&P 500 in the past week and month, which may indicate a potential turnaround.